

FATE THERAPEUTICS INC
Form 8-K
January 30, 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **January 27, 2015**

FATE THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of

incorporation)

001-36076
(Commission

File Number)

65-1311552
(I.R.S. Employer

Identification No.)

3535 General Atomics Court, Suite 200

Edgar Filing: FATE THERAPEUTICS INC - Form 8-K

San Diego, CA 92121

(Address of principal executive offices, including zip code)

(858) 875-1800

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 5.02 **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On January 29, 2015, Fate Therapeutics, Inc. (the "Company") entered into a one-year Consulting Agreement with Pratik Multani, M.D., M.S., the Company's Chief Medical Officer, pursuant to which Dr. Multani will assist the Company as a consultant supporting the Company's execution of its clinical trials of PROHEMA and development of its programmed mobilized peripheral blood product candidate. Dr. Multani provided notice to the Company on January 27, 2015 of his intent to end his employment with the Company, effective February 13, 2015, to pursue a career opportunity outside of the hematopoietic cell therapeutics field. The Company has initiated efforts to recruit a successor to Dr. Multani's role at the Company.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 30, 2015

Fate Therapeutics, Inc.

By:

/s/ J. Scott Wolchko

J. Scott Wolchko

Chief Financial Officer and Chief Operating Officer